Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Dose Escalation of Oral 5-Aminosalicylic Acid for Ulcerative Colitis With a Mayo Endoscopic Subscore of 1: An Open Label Randomized Controlled Trial.
Fukuda T, Aoki Y, Kiyohara H, Yokoyama A, Nakazawa A, Yoshimatsu Y, Sugimoto S, Nanki K, Mikami Y, Fukuhara K, Mizuno S, Sujino T, Mutaguchi M, Takabayashi K, Morohoshi Y, Hosoda Y, Ogata H, Iwao Y, Naganuma M, Kanai T. Fukuda T, et al. Among authors: yoshimatsu y. Inflamm Bowel Dis. 2024 Apr 24:izae088. doi: 10.1093/ibd/izae088. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38655866
Epigenetic regulation of T helper cells and intestinal pathogenicity.
Hagihara Y, Yoshimatsu Y, Mikami Y, Takada Y, Mizuno S, Kanai T. Hagihara Y, et al. Among authors: yoshimatsu y. Semin Immunopathol. 2019 May;41(3):379-399. doi: 10.1007/s00281-019-00732-9. Epub 2019 Mar 19. Semin Immunopathol. 2019. PMID: 30891628 Review.
Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease.
Igaki K, Nakamura Y, Tanaka M, Mizuno S, Yoshimatsu Y, Komoike Y, Uga K, Shibata A, Imaichi H, Takayuki S, Ishimura Y, Yamasaki M, Kanai T, Tsukimi Y, Tsuchimori N. Igaki K, et al. Among authors: yoshimatsu y. Inflamm Res. 2019 Jun;68(6):493-509. doi: 10.1007/s00011-019-01234-y. Epub 2019 Apr 10. Inflamm Res. 2019. PMID: 30972425
Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey.
Naganuma M, Sugimoto S, Suzuki H, Matsuno Y, Araki T, Shimizu H, Hayashi R, Fukuda T, Nakamoto N, Iijima H, Nakamura S, Kataoka M, Tamura Y, Tatsumi K, Hibi T, Suzuki Y, Kanai T; INDIGO survey Group. Naganuma M, et al. J Gastroenterol. 2019 Oct;54(10):891-896. doi: 10.1007/s00535-019-01591-9. Epub 2019 May 17. J Gastroenterol. 2019. PMID: 31102012
Development of an Indigo Naturalis Suppository for Topical Induction Therapy in Patients with Ulcerative Colitis.
Yoshimatsu Y, Naganuma M, Sugimoto S, Tanemoto S, Umeda S, Fukuda T, Nomura E, Yoshida K, Ono K, Mutaguchi M, Nanki K, Mizuno S, Mikami Y, Fukuhara K, Sujino T, Takabayashi K, Ogata H, Iwao Y, Kanai T. Yoshimatsu Y, et al. Digestion. 2020;101(4):492-498. doi: 10.1159/000501152. Epub 2019 Jun 25. Digestion. 2020. PMID: 31238326 Clinical Trial.
Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Fukuda T, Naganuma M, Takabayashi K, Hagihara Y, Tanemoto S, Nomura E, Yoshimatsu Y, Sugimoto S, Nanki K, Mizuno S, Mikami Y, Fukuhara K, Sujino T, Mutaguchi M, Inoue N, Ogata H, Iwao Y, Abe T, Kanai T. Fukuda T, et al. Among authors: yoshimatsu y. J Gastroenterol Hepatol. 2020 Nov;35(11):1878-1885. doi: 10.1111/jgh.15059. Epub 2020 Apr 20. J Gastroenterol Hepatol. 2020. PMID: 32250471 Free PMC article.
Pulmonary Arterial Hypertension Caused by AhR Signal Activation Protecting against Colitis.
Hiraide T, Teratani T, Uemura S, Yoshimatsu Y, Naganuma M, Shinya Y, Momoi M, Kobayashi E, Hakamata Y, Fukuda K, Kanai T, Kataoka M. Hiraide T, et al. Among authors: yoshimatsu y. Am J Respir Crit Care Med. 2021 Feb 1;203(3):385-388. doi: 10.1164/rccm.202009-3385LE. Am J Respir Crit Care Med. 2021. PMID: 33052717 Clinical Trial. No abstract available.
Bacteriotherapy for inflammatory bowel disease.
Yoshimatsu Y, Mikami Y, Kanai T. Yoshimatsu Y, et al. Inflamm Regen. 2021 Jan 13;41(1):3. doi: 10.1186/s41232-020-00153-4. Inflamm Regen. 2021. PMID: 33441186 Free PMC article. Review.
204 results